Immunotherapy has brought promising breakthroughs to several types of cancer. Cervical cancer has a relatively large number of mutations (gene changes), which may make it more sensitive to immunotherapy drugs and may apply immunotherapy to cervical cancer.
A number of clinical trials are in full swing, and the researchers recently summarized a phase II trial of single drug nivolumab (Opdivo) for recurrent cervical cancer. Among the 24 patients: 19 had cervical cancer, 5 had vaginal cancer, and 26% of cervical cancer patients responded to the drug, which is an encouraging result.
Researchers will continue to improve the single-drug program through further trials, but are also pursuing another approach: combination trials. Studies using single-agent immunotherapy with drugs such as pembrolizumab (Keytruda) or nivolumab show that 15% -25% of patients are active, but the remaining patients are inactive, and there is much room for improvement. For this reason, the researchers are more focused on combined trials of cervical cancer.
ການທົດລອງ ກຳ ລັງ ດຳ ເນີນຢູ່ໃນການຈັບຄູ່ກັບການປ້ອງກັນພູມຄຸ້ມກັນທີ່ໄດ້ຮັບຜົນກະທົບຈາກການຮັບປະທານອາຫານທີ່ກິນໄດ້ຄືzukizizab (Tecentriq) ກັບຕົວແທນ bevacizumab, ເຊິ່ງປ້ອງກັນບໍ່ໃຫ້ຈຸລັງມະເລັງສ້າງເປັນເສັ້ນເລືອດ ໃໝ່ ທີ່ຕ້ອງການຈະເລີນເຕີບໂຕ. Bevacizumab ແມ່ນຢາທີ່ມີການເຄື່ອນໄຫວຕ້ານມະເຮັງປາກມົດລູກ, ແລະມີຂໍ້ມູນ preclinical ທີ່ bevacizumab ສາມາດປັບປຸງປະສິດທິພາບຂອງການປິ່ນປົວດ້ວຍພູມຕ້ານທານ. ເພາະສະນັ້ນ, ນີ້ແມ່ນການລວມກັນທີ່ ໜ້າ ຕື່ນເຕັ້ນຂອງມະເຮັງປາກມົດລູກ, ແລະພວກເຮົາ ກຳ ລັງລໍຖ້າຜົນໄດ້ຮັບຂອງການສຶກສາຄັ້ງນີ້ຢ່າງກະຕືລືລົ້ນ.
In another clinical trial, researchers are studying how two immunotherapy drugs, durvalumab (IMFINZI) and tremelimumab, can be combined with radiation therapy to see if radiation can enhance the immune response.
ການຄົ້ນຄ້ວາການຮັກສາໂຣກມະເຮັງປາກມົດລູກນັບມື້ນັບຫຼາຍໄດ້ເພີ່ມຄວາມຫວັງອັນໃຫຍ່ຫຼວງໃຫ້ຜູ້ປ່ວຍມະເຮັງປາກມົດລູກ, ແລະພວກເຮົາຫວັງວ່າຈະໄດ້ຮັບຜົນດີໃນການຮັກສາ.
